期刊文献+

结直肠癌肝转移生存分析 被引量:11

Liver metastases of colorectal cancer:a survival analysis
原文传递
导出
摘要 目的分析结直肠癌肝转移病人的生存状况和相关影响因素。方法回顾性分析2000—2010年复旦大学附属中山医院收治的结直肠癌肝转移病人的临床资料、病理、治疗策略等情况,进行生存状况分析,并采用单因素和Cox比例风险回归模型等分析影响结直肠癌肝转移生存的相关因素。结果结直肠癌肝转移病人总体中位生存期22.0个月,5年存活率为16%,其中同时性肝转移为21.2个月和16%,异时性肝转移为30.1个月和23%,同时性肝转移组的存活率明显低于异时性肝转移组(P〈0.01)。按治疗方式分组,手术组病人的中位生存期为49.8个月,5年存活率为37%,显著优于化疗组(22.2个月和0)、介入组(19.0个月和11%)、化疗+介入组(22.8个月和10%)、局部治疗组(28.5个月和0)。同时性肝转移、肠癌原发灶分化Ⅲ-Ⅳ级、肝转移灶≥4个、最大肝转移灶≥5cm和肝转移灶非手术处理是影响病人预后的独立危险因素。结论同时性肝转移病人生存期低于异时性肝转移。积极手术治疗可以改善病人存活率。扩大肝转移灶切除的适应证对病人存活率无显著影响。独立危险因素的评分体系可以评估病人的预后。 Objective To investigate survival in patients with liver metastases of colorectal cancer and identify risk factors associated with survival.Methods Clinical,pathologic,treatment and complete follow-up data of the consecutive cases of colorectal liver metastasis admitted between 2000 and 2010 in Zhongshan Hospital of Fudan University were analyzed retrospectively.The prognostic value of different factors was studied through univariate and multivariate analyses.Results The median survival was 22.0 months and 5-year survival rate was 16%.Survival of synchronous liver metastases(21.2 months and 16%)was lower than that of metachronous liver metastases(30.1 months and 23%,P〈0.01).Survival after resection of liver metastases was 49.8 months and 37%,which was higher than that after chemotherapy(22.2 months and 0),that after intervention(19.0 months and 11%),that after chemotherapy combined with intervention(22.8 months and 10%)and that after local regional treatment(28.5 months and 0).Five factors were found to be significant and independent predictors of poor survival by multivariate analysis:simuhaneous liver metastases(P=0.005),poorly differentiated primary(P=0.005),number of liver metastases≥4(P=0.008),largest liver metastases≥5 cm(P=0.007),and no surgical treatment of liver metastases(P〈0.001).Conclusion Survival of synchronous liver metastases is lower than that of metachronous liver metastases.Resection of liver metastases provides good long-term survival benifit for patients with resectable and initially irreseetable liver metastases.Expansion of the indications for liver resection is acceptable.Long-term survival outcome can be predicted from a risk factor scoring system.
作者 朱德祥 任黎 韦烨 钟芸诗 刘天舒 叶清海 梁立 潘向欧 翟升永 徐博 许剑民 樊嘉 秦新裕 ZHU De-xiang;REN Li;WEI Ye(Institute of General Surgery,Zhongshan Hospital,Fudan University,Shanghai 200032,China)
出处 《中国实用外科杂志》 CSCD 北大核心 2011年第11期1022-1026,共5页 Chinese Journal of Practical Surgery
基金 卫生部部属(管)医院临床学科重点项目(2010-2012年度项目) 2009年上海市科委生物医药处面上项目(09411967100) 2008年上海市科委重点课题(08431910200) 2009年国家自然科学基金项目(30973416)
关键词 结直肠癌肝转移 生存分析 liver metastases of colorectal cancer survival analysis
  • 相关文献

参考文献22

  • 12007年上海市恶性肿瘤发病率[J].上海预防医学,2010,22(7):399-399. 被引量:9
  • 2Xu J, Qin X, Wang J, et al. Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer[J]. J Cancer Res Clin Oncol, 2011,137(9): 1379-1396.
  • 3Kopetz S, Chang GJ, Overman M J, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepat- ic resection and improved chemotherapy[J]. J Clin Oncol, 2009, 27(22): 3677-3683.
  • 4Adam R, Hoti E, Bredt LC. Evolution of neoadjuvant therapy for extended hepatic metastases-have we reached our (non-resect- able) limit? [J]. J Surg Oncol, 2010, 102(8): 922-931.
  • 5Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemo- therapy with FOLFOX4 and surgery versus surgery alone for re- sectable liver metastases from colorectal cancer (EORTC Inter- group trial 40983): a randomised controlled trial [J]. Lancet, 2008, 371(9617): 1007-1016.
  • 6Chiappa A, Bertani E, Makuuchi M, et al. Neoadjuvant chemo therapy followed by hepatectomy for primarily resectablcolorectal cancer liver metastases [J]. Hepatogastroenterologyt 2009, 56(91-92): 829-834.
  • 7Adam R, Bhangui P, Poston G, et al. Is perioperative chemother- apy useful for solitary, melachronous, colorectal liver metasta- ses? [J]. Ann Surg, 2010, 252(5): 774-787.
  • 8Cleary JM, Tanabe KT, Lauwers GY, et aL Hepatic toxicities as- sociated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver[J]. On- cologist, 2009, 14(11): 1095-1105.
  • 9Gaujoux S, Go6r6 D, Dumont F, et al. Complete radiological re-sponse of colorectal liver metastases after chemotherapy: what can we expect? [J]. Dig Surg, 2011, 28(2): 114-120.
  • 10de Haas R J, Adam R, Wicherts DA, et al. Comparison of simul- taneous or delayed liver surgery for limited synchronous colorectal metastases [ J ]. Br J Surg, 2010, 97(8): 1279-1289.

共引文献8

同被引文献83

引证文献11

二级引证文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部